
Akagera Medicines Reports Positive Early Results for Long-Acting TB Drug
A clinical-stage trial of the intravenous therapeutic AKG-100 has demonstrated favorable safety and potent bactericidal activity in patients with pulmonary tuberculosis. The findings suggest that a single dose could provide therapeutic coverage for up to 28 days, potentially replacing the standard regimen of daily oral medication.




















.png)



